Good morning, everyone, and how you today? We are doing just fine, thank you, since a cool breeze and shiny sun are enveloping the unusually placid Pharmalot campus. Our official mascot is curled up quietly nearby, the coffee kettle is approaching a boil, and a few happy birds are chirping nearby. Such serenity, however, can last only so long. In other words, it is time to get cracking. On that note, here are a few items of interest to help you get started on your own journey.

A federal judge reviewing a Justice Department decision to allow CVS Health (CVS) to merge with Aetna ruled that the agreement was in fact legal under antitrust law, Reuters tells us. The judge was examining a government plan to allow the merger on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans (WCG). Both deals closed. The judge initially balked at approving the conditions and insisted on hearing from critics. He complained, however, at the common practice of closing deals while a court review was still in process.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy